Podcasts about biomarkers

What if some of the most disabling symptoms in EDS, HSD, POTS, MCAS, ME/CFS, and long COVID are being driven by something we still struggle to see on standard testing? In this episode of Bendy Bodies, Dr. Linda Bluestein is joined by guest co-host Dr. Ina Stephens, Associate Director of the UVA Health EDS and Hypermobility Disorder Center, along with Brain Inflammation Collaborative co-founder Christy Jagdfeld and neuroscientist Dr. Megan Fitzgerald. Together, they explore the rapidly evolving science of brain inflammation, including what it actually means, how it differs from conditions like encephalitis or brain edema, and why it may matter in complex multisystem illness. The conversation dives into microglial activation, mast cell involvement in the central nervous system, and the challenge of detecting subtle neuroinflammation in living patients. The guests also discuss emerging research tools, including ultra-high-field MRI, PET ligands, and blood-based extracellular vesicles, that may eventually give clinicians a clearer window into what is happening inside the brain. The group also takes a closer look at the Brain Inflammation Collaborative's Unhide platform, which is collecting real-world, patient-reported data across more than 30 overlapping chronic conditions, including EDS, POTS, MCAS, ME/CFS, and long COVID. Early findings raise important questions about quality of life, symptom burden, the limitations of the Beighton score, and why pediatric research may be especially important. The episode closes with practical implications, including why pacing matters when exercise can worsen symptoms rather than improve them, and what patients and clinicians should watch as this field moves forward. Takeaways “Brain inflammation” can involve subtle processes such as microglial activation and mast cell signaling that may not appear on routine MRI or CT scans. Emerging tools such as ultra-high-field MRI, PET imaging, and blood-based extracellular vesicles may eventually help researchers detect and track neuroinflammation in living patients. The Unhide platform has collected real-world data from thousands of participants with overlapping chronic conditions, offering a new way to study symptom burden and quality of life outside traditional clinical trials. The Beighton score may not reflect functional severity or symptom burden, highlighting the need for better ways to assess hypermobility over time. Pediatric research is urgently needed to understand how these conditions develop and whether earlier recognition could change long-term outcomes. Want more of the Brain Inflammation Collaborative? https://www.unhidenow.org/ https://www.braininflammation.org/ Want to learn more about the UVA EDS Center? For Appointments and Questions: RUVAEDSCenter@uvahealth.org UVA EDS: https://www.uvahealth.com/healthy-practice/advancing-care-through-ehlers-danlos-clinic UVA EDS FAQ: https://www.uvahealth.com/support/eds/faq UVA Pediatric Integrative Medicine: https://childrens.uvahealth.com/specialties/integrative-health Want more Dr. Linda Bluestein, MD? Website: https://www.hypermobilitymd.com/ YouTube: https://www.youtube.com/@bendybodiespodcast Instagram: ⁠⁠⁠⁠https://www.instagram.com/hypermobilitymd/⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠https://www.facebook.com/BendyBodiesPodcast⁠⁠⁠⁠ X: ⁠⁠⁠⁠https://twitter.com/BluesteinLinda⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠https://www.linkedin.com/in/hypermobilitymd/⁠⁠⁠⁠ Newsletter: ⁠⁠⁠⁠https://hypermobilitymd.substack.com/ Shop my Amazon store ⁠⁠⁠ https://www.amazon.com/shop/hypermobilitymd Dr. Bluestein's Recommended Herbs, Supplements and Care Necessities: https://us.fullscript.com/welcome/hypermobilitymd/store-start Thank YOU so much for tuning in. We hope you found this episode informative, inspiring, useful, validating, and enjoyable. Join us on the next episode for YOUR time to level up your knowledge about hypermobility disorders and the people who have them. Join YOUR Bendy Bodies community at ⁠⁠https://www.bendybodiespodcast.com/⁠⁠. YOUR bendy body is our highest priority!⁠⁠ Learn more about Human Content at ⁠⁠⁠http://www.human-content.com⁠⁠⁠ Podcast Advertising/Business Inquiries: ⁠⁠⁠sales@human-content.com⁠⁠⁠ Part of the Human Content Podcast Network Go to AirDoctorPro.com and use promo code BENDY_ to get UP TO $300 off today! FTC: This video is not sponsored. Links are commissionable, meaning I may earn commission from purchases made through links Chapters: 00:00 Beighton Score Debate00:28 Meet the Guests02:54 Why BIC Was Founded07:22 Defining Brain Inflammation09:44 Biomarkers and Imaging Advances18:12 Unhide Platform and Real World Data25:55 Comorbidities and Survey Cadence31:40 Survey Fatigue Solutions32:49 Tools Beyond Beighton34:16 Research Priorities Wish List35:41 Biomarkers EVs Immune Profiling38:37 Pediatric Focus Early Signs46:34 Building Pediatric Platform53:07 Hacks Resources And Wrap Up Learn more about your ad choices. Visit megaphone.fm/adchoices

Drs. Griffiths and Chase explain type 2–high asthma as a multisystem inflammatory disease that often coexists with conditions like allergic rhinitis, sinus disease with polyps, eczema, food allergies, and eosinophilic esophagitis. They emphasize the importance of recognizing type 2–high patterns through history and biomarkers; they also discuss the roles of multidisciplinary care, optimized inhaler use, reduced steroid exposure, and targeted biologic therapy when asthma remains uncontrolled.

In this Huberman Lab Essentials episode, my guest is Dr. Sara Gottfried, M.D., a Harvard-trained, board-certified gynecologist and expert in female hormone health. We discuss the key biomarkers women should track at each stage of life and how cortisol, thyroid hormone, estrogen, progesterone, and testosterone shape energy, mood, metabolism, and long-term disease risk. We also discuss PCOS, the risks and benefits of oral contraceptives, and the shift in brain metabolism that begins in perimenopause. Dr. Gottfried explains actionable tools for hormone and micronutrient testing, nutrition, stress management, and cardiometabolic screening that women can use at any age. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman LMNT: https://drinklmnt.com/huberman Eight Sleep: https://eightsleep.com/huberman Timestamps (00:00:00) Female Hormone Health (00:00:24) Family History, Intergenerational Trauma; Endometriosis, Fibroids, PCOS (00:01:31) Biomarkers by Decade; Teens & Cortisol; 20s & Sex Hormones (00:03:35) Tool: Hormone Test Timing; Micronutrient Testing, Magnesium (00:05:41) Sponsor: LMNT (00:07:17) Tool: Smoothies, Greens Powders & Microbiome (00:08:12) Nutrient Panels, Antioxidants, B Vitamins, Glutathione (00:09:34) Constipation, Thyroid Dysfunction; Trauma & Female Physiology (00:11:50) Tools: Reduce Perceived Stress, Meditation, Yoga, Breathwork (00:13:30) Opportunities by Decade; Androgens & Testosterone Decline (00:14:50) PCOS, Diagnostic Criteria, Hirsutism, Cardiometabolic Risk (00:17:10) Insulin & Glucose; Tool: Continuous Glucose Monitors (00:18:05) Democratizing Health Data (00:18:52) Sponsor: AG1 (00:20:07) Longevity "Don'ts"; Chronic Cardio & Cortisol; Tool: Adaptive Exercise (00:22:46) Oral Contraceptives, Benefits & Ovarian Cancer Risk (00:24:27) Ovarian Cancer Symptoms, Bloating, CA-125 (00:25:51) Oral Contraceptive Risks, Progestins, Inflammation; SHBG & Testosterone (00:29:08) Clitoral Shrinkage; Tools: Alternatives for Painful Periods (00:30:14) Sponsor: Eight Sleep (00:31:32) Menopause & Perimenopause; 30s Hormonal Baseline (00:33:07) Female Brain, Cerebral Hypometabolism & Alzheimer's Risk (00:35:02) Slow Brain Energy, Hormone Therapy; Hot Flashes as Biomarkers (00:36:54) Tool: Coronary Artery Calcium Score Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

How can we best manage intermediate-risk bladder cancer to balance disease control, quality of life, and the growing range of treatment options? On this episode of the BackTable Urology Podcast, Dr. Ruchika Talwar interviews Dr. Charles “Chaz” Peyton about the challenges of treating recurrent low-grade, intermediate-risk non–muscle invasive bladder cancer. They highlight the high recurrence but low progression risk, the often-underappreciated impact of repeated TURBTs on patient well-being, and the evolving landscape of office-based and chemoablative therapies. --- Get the BackTable app https://www.backtable.com/app --- Timestamps 00:00 - Introduction05:58 - Comparing Office Ablation and OR TURBT08:26 - TURBT Impact on Quality of Life11:37 - Uncovering Hidden Patient Burdens and Costs14:44 - Integrating Chemoablation into Practice18:20 - ENVISION QoL Study Setup22:04 - Comparing TURBT Preferences27:40 - Counseling Risk-Averse Patients29:10 - Community Adoption Advice31:59 - Upcoming Clinical Trials35:28 - Biomarkers and Expanding Access36:23 - Final Thoughts and Closing Remarks --- More about this episode The conversation covers practical strategies like office-based surveillance and fulguration for small recurrences, identifying triggers for returning to the OR, and recognizing the hidden burdens of TURBT complications such as hematuria, incontinence, and unplanned ER visits. Dr. Peyton reviews the role of chemoablative options for selected patients, discusses trial data on patient-reported outcomes, and addresses the mixed evidence, high costs, and need for individualized decision-making. The episode also explores new intravesical and FGFR-targeted therapies, underscores the importance of cost-conscious adoption and biomarkers, and considers how management approaches must evolve, especially in community practice settings. --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Send us Fan MailA 27 year old woman went to a longevity clinic in the Bronx for an NAD IV drip. Minutes later she was in cardiac arrest. She died a few hours after that. The person who ran the clinic held a medical license from the Dominican Republic, not the United States.Dr. Kevin White talks with Dr. Matt Kaeberlein, a researcher who studies why and how we age, about what that story actually tells us. His answer isn't really about NAD. It's about certainty. Kaeberlein has never seen evidence that NAD infusions help anyone, and the field's founding claim, that NAD declines with age and needs replacing, is now being questioned by the same scientists who study it. Clinics keep selling it with total confidence anyway.That same pattern shows up everywhere they go in this conversation. Kaeberlein now chairs Montana's expanded Right To Try review board, which lets biotech companies test experimental therapies on real patients once they clear a phase one safety bar, outside the usual FDA process. He explains why that could produce safety data the field has never had, and why he'd reject any therapy pitched without a real scientific rationale behind it, no matter how confidently it's sold."You don't want to listen to the people who are telling you with a hundred percent certainty, do this. And by the way, you know, buy my longevity latte."                                                    — Matt KaeberleinThey also compare LinAge2, a biological age calculator built from standard bloodwork with decades of mortality data behind it, to the consumer epigenetic age tests sold directly to the public. Kaeberlein's problem with the popular tests has nothing to do with the underlying science. It's that nobody selling them will publish the error bars, so a 20 year gap on your result could mean everything or nothing. You can't run statistics on a number you're not allowed to check.Along the way they cover why rapamycin, the drug most associated with Kaeberlein's name, might not even be his top pick anymore. A company spun out of his lab, Aura Biomedical, has found longevity molecules that also protect against radiation damage. And a new epigenetic instability test from Irena Conboy's company, Generation Lab, measures something closer to biological chaos than biological age.Follow The Daily Apple and leave a review to help more people find the show. Instagram: @KevinWhiteMDYouTube: @KevinWhiteMD Prime Health Associates

Up until just a couple years ago, an 85-year-old patient presenting with gradual, amnestic memory loss was almost automatically presumed to have Alzheimer's disease. However, new biomakers and the recognition of conditions like Limbic-predominant age-related TDP-43 encephalopathy (LATE) are reshaping our understanding of cognitive decline in older adults. It's looking more clear that pure Alzheimers dementia is rare in older adults, and co-occurring pathologies that may include Alzheimer's, LATE, Lewy Body, and vascular neuropatholigies, are the rule rather than the exception.  In this episode of the GeriPal Podcast, we sit down with Sterling Johnson and Nate Chin from the University of Wisconsin. Sterling is a clinical neuropsychologist and researcher who leads the CLARiTI study, which is attempting to uncover the intersecting causes of dementia.  Nate is the medical director and Clinical Core Co-Leader for the Wisconsin Alzheimer's Disease Research Center (ADRC), the host of the Dementia Matters podcast, and author of a new book When Memory Fades.   We tackle the real-world complexity of mixed dementia and its major diagnostic and clinical treatment dilemmas. We also go in deep to discuss LATE, from what it is, to how it presents, to whether it should change how we think about using newly approved disease-modifying therapies when a patient has confirmed amyloid positivity alongside suspected LATE.  

Susan Wood, CEO of VIDA, develops AI-driven imaging-based biomarkers that quantitatively measure biological processes and disease states using imaging modalities such as CT, MRI, PET, and ultrasound. Unlike traditional visual image analysis, VIDA's technology extracts approximately 25,000 measurements per imaging timepoint, enabling detection of therapeutic responses at the sub-millimeter level. This convergence of advanced scanner technology, high-quality imaging data, and AI-powered analysis represents a significant new frontier in precision medicine and drug development. Susan explains, "I'll start with what VIDA brings in. Our background has been the development and validation of AI-driven imaging-based biomarkers. I'll start by defining a biomarker, specifically an imaging-based biomarker. It's a quantitative measurement derived from an imaging modality. An imaging modality can be a CT scan, an MRI, a PET scan, or an ultrasound, and the measurement reflects a biological process, a disease state, or a response to therapy. VIDA's formation was focused on the production and validation of those imaging-based biomarkers and on incorporating them into provider-based clinical workflows as well as clinical trial or drug development workflows." "I would say that in general, traditionally radiology has relied on radiologic images, those imaging modalities have been read visually. And if you read an image visually, there's just a fraction of information that you can get from those images versus reading them with these AI-generated processes. So there's less than 1% of that image you'll be able to understand the extent and the complexity of the measurements that image can offer. We read, or we combine that visual reading with a highly quantitative process. So for each imaging time point, we'll measure 25,000 measurements per imaging time point. Obviously that's well beyond what a human eye could do just from an efficiency standpoint, but certainly from a precision standpoint, they wouldn't be able to measure that level of precision in the imaging by an eyeball alone." #VIDA #AI #DigitalBiomarkers #MedicalImaging #Radiology #ClinicalTrials #DrugDevelopment #PrecisionMedicine #HealthcareInnovation #RespiratoryCare vidalung.ai Download the transcript here

Susan Wood, CEO of VIDA, develops AI-driven imaging-based biomarkers that quantitatively measure biological processes and disease states using imaging modalities such as CT, MRI, PET, and ultrasound. Unlike traditional visual image analysis, VIDA's technology extracts approximately 25,000 measurements per imaging timepoint, enabling detection of therapeutic responses at the sub-millimeter level. This convergence of advanced scanner technology, high-quality imaging data, and AI-powered analysis represents a significant new frontier in precision medicine and drug development. Susan explains, "I'll start with what VIDA brings in. Our background has been the development and validation of AI-driven imaging-based biomarkers. I'll start by defining a biomarker, specifically an imaging-based biomarker. It's a quantitative measurement derived from an imaging modality. An imaging modality can be a CT scan, an MRI, a PET scan, or an ultrasound, and the measurement reflects a biological process, a disease state, or a response to therapy. VIDA's formation was focused on the production and validation of those imaging-based biomarkers and on incorporating them into provider-based clinical workflows as well as clinical trial or drug development workflows." "I would say that in general, traditionally radiology has relied on radiologic images, those imaging modalities have been read visually. And if you read an image visually, there's just a fraction of information that you can get from those images versus reading them with these AI-generated processes. So there's less than 1% of that image you'll be able to understand the extent and the complexity of the measurements that image can offer. We read, or we combine that visual reading with a highly quantitative process. So for each imaging time point, we'll measure 25,000 measurements per imaging time point. Obviously that's well beyond what a human eye could do just from an efficiency standpoint, but certainly from a precision standpoint, they wouldn't be able to measure that level of precision in the imaging by an eyeball alone." #VIDA #AI #DigitalBiomarkers #MedicalImaging #Radiology #ClinicalTrials #DrugDevelopment #PrecisionMedicine #HealthcareInnovation #RespiratoryCare vidalung.ai Listen to the podcast here

In this episode of Mind the Meds, host Erica Marini, PharmD, MS, BCPS, welcomes Jenelle Hall Montgomery, PharmD, BCACP, CPP, a clinical pharmacist practitioner with Duke Neurological Disorders Clinic at Duke University Hospital, to discuss highlights from the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting in Charlotte, North Carolina, where Montgomery was recognized as a Giant of Multiple Sclerosis. Before the CMSC discussion, Marini runs through a roundup of recent neurology news, including approval of at-home initiation dosing for lecanemab-irmb (Leqembi; Eisai, Biogen), fast track designation for remlifanserin (Acadia Pharmaceuticals) in Alzheimer disease psychosis, approval of the oral PCSK9 inhibitor enlicitide (Lipfendra; Merck), and phase 3 data on tavapadon (AbbVie) for Parkinson disease showing a lower rate of impulse control disorders than traditional dopamine agonists.The pharmacists then turn to CMSC sessions on off-label and evolving areas of MS care. They discuss growing interest in neurofilament light chain as a biomarker for tracking subclinical disease progression over time, along with the ongoing debate over when it is safe to discontinue disease-modifying therapy (DMT) in older, stable patients. Both note their practices generally begin this conversation around 60 to 65 years of age, factoring in radiographic and clinical stability over the preceding decade, and describe strategies such as tapering dosing frequency or switching to lower-efficacy agents rather than abrupt discontinuation.The conversation closes with an update on family planning in MS, where new data presented at CMSC reinforce the safety of anti-CD20 therapies during pregnancy and breastfeeding. Montgomery and Marini review a 10-year dataset of about 5000 pregnancies on ocrelizumab (Ocrevus; Genentech), a large safety analysis of ofatumumab (Kesimpta; Novartis Pharmaceuticals) showing no increase in birth malformations, and early transfer-into-breastmilk data on ublituximab (Briumvi; TG Therapeutics). They also touch on the limited but growing evidence for GLP-1 receptor agonists in patients with MS, noting no known drug interactions with DMTs and possible indirect benefit through weight-related disease modulation, though neither pharmacist currently prescribes GLP-1s for an MS indication.Key Takeaways:1. Neurofilament light chain is emerging as a useful, though not yet mainstream, biomarker in MS. Rather than a single value, tracking neurofilament light chain over time alongside clinical status may help identify subclinical disease progression, particularly in patients without clear relapses.2. DMT discontinuation in older, stable patients remains individualized, with most practices starting the conversation around 60 to 65 years of age. Clinicians weigh 10-year clinical and radiographic stability, and some patients opt for a gradual step-down in dosing frequency or a switch to a lower-efficacy agent rather than outright discontinuation.3. New pregnancy and breastfeeding safety data continue to support anti-CD20 therapies as a preferred family planning strategy in MS. A 10-year, 5000-pregnancy dataset on ocrelizumab, reassuring malformation data on ofatumumab, and early breastmilk transfer data on ublituximab are strengthening patient counseling conversations around conception, pregnancy, and postpartum DMT resumption.

GI cancer nurses Alana Fitzgibbon (Hobart) and Catherine Trevaskis (Canberra) discuss the shift toward biomarker-driven care in gastric and gastro-oesophageal junction cancer, centred on the newly available targeted therapies — so nurses can help patients stay on treatment and receive the full benefit of this new personalised medicine. This is a member-only episode. Access the full podcast by entering your log in details at https://www.cnsa.org.au/

Can advanced technology help us predict, prevent, and optimize our future health? In this episode, Dr. Adrijana Kekic, Founder and CEO of Futurome, explores how precision medicine, AI-driven insights, and advanced biological data are transforming the way we approach longevity. As a longevity pharmacist and expert in systems biology, Dr. Kekic helps executives, leaders, and high performers move beyond traditional health assessments by combining multiomics, digital biomarkers, pharmacogenomics, and personalized strategies designed to extend both lifespan and healthspan. In this conversation, we explore: ·       How multiomics reveals deeper insights into individual health and biology. ·       Why standard blood tests may miss important signals behind ongoing symptoms. ·       How pharmacogenomics helps predict individual responses to medications. ·       The role of AI, digital twins, and predictive health modeling in future medicine. ·       What cellular drift means and why detecting early changes matters. This episode offers a glimpse into the future of proactive healthcare—where personalized data, advanced technology and precision strategies help individuals take control of aging and long-term wellness. Connect with Dr. Adrijana Kekic and Futurome through their website, Instagram, LinkedIn and Youtube!. Episode also available on Apple Podcasts: https://apple.co/38oMlMr

Longevity expert Dr Florence Comite joins me to explain why testosterone, not estrogen, drives body composition and ageing in midlife women. Decline isn't inevitable - it's programmable. She unpacks why testosterone (which women carry in larger amounts than estrogen) drives muscle, visceral fat and brain fog from your 30s on, why only a third of us should fast, and the five biomarkers - fasting glucose, HbA1c, fasting insulin, cholesterol risk ratio and free testosterone - that predict where your healthspan is headed and how to change it. WHAT YOU'LL LEARN Why women carry more circulating testosterone than estrogen, and what its decline does to muscle, visceral fat and cognition from your 30s What "I don't feel like myself anymore" is actually signalling beneath the surface How cortisol quietly drives the anxiety-out-of-nowhere, the 2am wake-ups and the stubborn weight around your middle Why only a third of women should fast, and the 3-hour glucose test that tells you which third you're in What the five non-negotiable biomarkers reveal about where your healthspan is headed TIMESTAMPS 00:00 Intro: Why You Don't Feel Like Yourself After 35 - Peak Health, Testosterone Decline & the 30s Shift 05:52 - Perimenopause, Cortisol & Anxiety Out of Nowhere: Belly Fat, Sleep and the Caregiver Load 13:28 - Wearables, CGM & the Fasting Third/Third/Third: Measuring How Your Body Really Ages 20:11 - Who Should Actually Fast: The 3-Hour Glucose Test, Protein at Every Meal & the Oatmeal Trap 27:00 - Testosterone for Body Composition & Energy: UK Access, the 2024 Study & Protein for Muscle 33:46 - The 5 Biomarkers That Predict How You Age - Plus the 7 Patterns of Health Decline 39:37 - Decade by Decade for Women vs Men: Bone Loss, Osteoporosis, Andropause & Owning Your Healthspan VALUABLE RESOURCES - Invincible (Dr Comite's new book): https://www.penguin.co.uk/books/475986/invincible-by-comite-florence/9781529977066  - Dr Florence Comite's website: https://www.comitemd.com/  - Follow Dr Comite on Instagram: https://www.instagram.com/drflorencecomite/  AlgaeCal Plus*‡: Science-backed supplements designed to support healthy aging

Most women think menopause is a hormone problem. Today's guest says many symptoms may actually begin in the gut–years before menopause. The science could completely change how you think about hot flashes, weight gain, inflammation, sleep, and even autoimmune disease.  Perimenopause and menopause affect nearly every system in the body, yet many women are told their symptoms are simply the result of changing hormones. But what if the gut microbiome is one of the missing pieces?  In this episode of the Uncover Your Eyes podcast, Dr. Meenal Agarwal sits down with Cynthia Thurlow, women's health expert, nurse practitioner, and bestselling author of The Menopause Gut, to explore the emerging science connecting gut health, hormones, metabolism, inflammation, immunity, and brain health during midlife. Together they explain why digestive changes often appear years before menopause, how the estrobolome influences estrogen metabolism, why food sensitivities suddenly develop, and how your gut may affect everything from sleep to weight loss. In this episode, you'll uncover:

Heart failure remains one of the leading causes of hospitalization among older adults worldwide. During episodes of acute decompensated heart failure (ADHF), excess fluid builds up in the lungs and body, making breathing difficult and increasing the risk of serious complications. Although intravenous loop diuretics such as furosemide are the standard treatment for relieving congestion, many patients continue to experience persistent inflammation, ongoing cardiac remodeling, and worsening heart function despite therapy. A research paper published in Volume 18 of Aging titled “Effects of intravenous furosemide plus small-volume hypertonic saline solutions on inflammatory, remodelling markers and epigenetics signatures of patients with congestive acute decompensated heart failure (ADHF),” investigated whether combining intravenous furosemide with small volumes of hypertonic saline solution (HSS) could improve biological markers associated with heart failure compared with furosemide alone. Full blog post - https://aging-us.org/2026/08/hypertonic-saline-plus-furosemide-improves-heart-failure-biomarkers-in-randomized-trial/ DOI - https://doi.org/10.18632/aging.206364 Corresponding author - Antonino Tuttolomondo - bruno.tuttolomondo@unipa.it Abstract video - https://www.youtube.com/watch?v=EG65XlcDJ3U Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206364 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, heart failure, acute decompensated heart failure, furosemide, hypertonic saline solution To learn more about the journal, please visit https://www.Aging-US.com​​ and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Can a drug-eluting bladder device change the treatment algorithm for BCG-unresponsive non–muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Ruchi Talwar interviews Dr. Sarah Psutka to explore the emerging role of a novel intravesical device that delivers sustained gemcitabine therapy for patients refusing or ineligible for cystectomy. They highlight new FDA-approved treatment options, real-world workflow considerations, and the clinical potential for continuous intravesical chemotherapy in a crowded therapeutic landscape. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by Johnson & Johnson https://www.inlexzohcp.com/ --- Timestamps 00:00 - Introduction02:40 - Why Focus on TAR-20005:35 - Device Basics07:05 - Dosing Schedule Explained11:17 - SUNRISE-01 Trial Results15:07 - Patient Selection and Contraindications20:52 - Indications for Device Removal23:26 - Clinic Workflow Learning Curve25:56 - Tips for Insertion and Device Deployment28:52 - Cystoscopy Findings and Surveillance Protocol32:16 - Treatment Sequencing38:43 - Future Trial and Research Directions45:16 - Biomarkers, AI, and Personalizing Care46:35 - Cost, Supportive Care, and Patient Burden48:42 - Closing Thoughts --- More about this episode The conversation dives into patient selection, preparation, and side effect management for TAR-200, as well as the key findings from the SUNRISE-01 trial. Dr. Psutka discusses dosing schedules, when to remove the device, and how to handle complications like UTI, hematuria, and LUTS. The episode also covers surveillance protocols, the impact on clinic operations, and the importance of balancing vigilant cancer surveillance with patient burden. Finally, they touch on future directions, including biomarkers, AI-assisted pathology, and optimizing the timing of cystectomy and supportive care for a more personalized approach to NMIBC. --- Resources TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Studyhttps://ascopubs.org/doi/10.1200/JCO-25-01651 SUO 2024: SunRISe-5: A Phase III, Randomized, Open-label Study of TAR-200 Compared with Intravesical Chemotherapy After Bacillus Calmette-Guerin in Recurrent, High-risk, Non-muscle Invasive Bladder Cancer SUO 2024: SunRISe-5: A Phase III, Randomized, Open-label Study of TAR-200 Compared with Intravesical Chemotherapy After Bacillus Calmette-Guerin in Recurrent, High-risk, Non-mushttps://www.urotoday.com/conference-highlights/suo-2024/suo-2024-bladder-cancer/156723-suo-2024-sunrise-5-a-phase-iii-randomized-open-label-study-of-tar-200-compared-with-intravesical-chemotherapy-after-bacillus-calmette-guerin-in-recurrent-high-risk-non-muscle-invasive-bladder-cancer.htmlcle Invasive Bladder Cancer Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Resultshttps://ascopubs.org/doi/10.1200/JCO-25-02382 INLEXZO - SunRISe-3 Studyhttps://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-sunrise-3-study --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

In this episode of #TheShot of Digital Health Therapy, Jim Joyce and I sit down with Jonathan Anderson, CEO of Nothing Artificial. Thoroughly enjoyed reconnecting and chatting across numerous topics: -The Door-to-Door Sales Rule: What Jon learned in his early days of selling home water systems to households (Hint: make sure all the decision makers are present at once) -The Enterprise Arbitrage: How Jon acquired UCB Pharma's FDA-registered Nile.ai platform turning enterprise infrastructure into a commercial launchpad. -The DTx Graveyard Realist: Why Akili and Pear struggled, and why digital therapeutics must shift from standalone "disease apps" to cognitive infrastructure embedded directly into pharma pipelines and everyday hardware. -Economic Inevitability vs. Hype: Why health systems don't adopt tech because it's novel or slick - they adopt when friction drops to zero and the business model becomes mathematically unavoidable. Ready to hear how real health-tech deals get structured when the PR filter is off? Listen to the full episode on Spotify, Apple Podcasts, or YouTube below (links are in the comments) !

Some of the best conversations don't happen on stage—they happen after the conference.Originally recorded following a previous Suisun Summit, this NeuroNoodle panel captures the discussions that were shaping the future of neurofeedback: biomarkers, QEEG, trauma, autism, ADHD, licensing, ethics, and why many clinicians are moving beyond diagnostic labels toward understanding brain function.With the 2026 Suisun Neuroscience Summit just around the corner, it's fascinating to revisit these conversations and see how many of these ideas continue to influence clinical practice today.

In this special episode of The Pet Food Science Podcast Show, our co-host Dr. Jan Suchodolski from Texas A&M University explains why validated analytical methods are essential for reliable pet nutrition and gastrointestinal research. He discusses assay development, biomarker validation, omics technologies, microbiome analysis, and the role of artificial intelligence in improving research quality and diagnostics. Listen now on all major platforms!"Without proper measurements, scientific discoveries about nutrition and health cannot produce reliable conclusions because inaccurate methods create uncertainty and reduce confidence in biological interpretation."Meet the guest: Dr. Jan Suchodolski is Professor, Purina PetCare Endowed Chair for Microbiome Research, Associate Director and Head of Microbiome Sciences at the Gastrointestinal Laboratory at Texas A&M University. His research focuses on gastrointestinal biomarkers, intestinal microbiota, and diagnostic development. He has published more than 400 scientific articles, received the 2024 AVMA Career Achievement in Canine Research Award. He also serves as co-host of The Pet Food Science Podcast Show. Listen to Dr. Jan Suchodolski on The Pet Food Science Podcast Show, available on all major platforms.Liked this one? Don't stop now — Here's what we think you'll love!Don't miss the chance to be part of the Pet Food Inner Circle!Join now and connect with leading experts in pet nutrition: https://petfoodinnercircle.com/What will you learn:(00:00) Highlight(01:16) Introduction(05:27) Assay validation basics(11:54) Discovery versus validation(18:33) Omics technologies(19:40) Bile acid biomarkers(26:04) Artificial intelligence(42:31) Final QuestionsThe Pet Food Science Podcast Show is trusted and supported by innovative companies like:* Trouw Nutrition* Kemin- Biorigin- Rangen Group- DietForge- WiseVAs- The Owner's Box- Elevate- ZentrixOS- Zentrix Insights

For decades, men with high-risk prostate cancer have routinely been told they need 18 to 36 months of androgen deprivation therapy (ADT) alongside radiation.But what if 12 months is enough?In this episode of the Dr. Geo Prostate Podcast, Dr. Geo Espinosa welcomes internationally recognized radiation oncologist Dr. Dan Spratt, Chair of Radiation Oncology at University Hospitals/Case Western Reserve University, to discuss groundbreaking research that could change how advanced prostate cancer is treated.Together they explore the latest MARCAP consortium data suggesting many men may receive the same cancer control with significantly less hormone therapy—potentially reducing years of unnecessary side effects while maintaining excellent outcomes. They also discuss how physicians personalize treatment decisions, the growing role of artificial intelligence with Artera AI, and why the future of prostate cancer treatment may involve doing less, not more.If you or someone you love is facing radiation therapy for prostate cancer, this episode provides one of the most important conversations happening in prostate cancer care today.What You'll Learn✔ Why 2-3 years of ADT may not be necessary for many patients✔ The new evidence supporting approximately 12 months of hormone therapy✔ Why longer hormone therapy can permanently affect testosterone recovery✔ How physicians balance cancer control with quality of life✔ The difference between NCCN guidelines and individualized patient care✔ Which patients may still benefit from longer hormone therapy✔ How AI (Artera AI) is helping personalize prostate cancer treatment✔ Why prostate cancer care is shifting toward treatment de-intensification✔ The future of precision medicine in radiation oncologyEpisode Timestamps00:00 Introduction01:30 Meet Dr Dan Spratt02:22 Why ADT Lasts Years05:42 How ADT Helps Radiation08:49 Personalizing ADT Duration12:39 Guidelines and Real World Use18:03 Who Needs Long Term ADT21:13 Artera AI Explained23:19 Old Data and Modern Outcomes27:28 De Intensification Future31:33 Biomarkers for Urologists33:57 Choosing Artera vs Decipher37:28 Final Takeaways and OutroKey Discussion PointsNew MARCAP consortium analysis on ADT durationRadiation sensitivity and androgen deprivationWhy many men never fully recover testosterone after prolonged ADTBalancing survival outcomes with quality of lifeShared decision-making between physician and patientGenomic classifiers including DecipherAI biomarkers and Artera AIPersonalized radiation oncologyModern imaging and PSMA PETDe-intensifying prostate cancer treatmentPrecision medicine in localized prostate cancerThe future of individualized prostate cancer careResources Mentioned• MARCAP Consortium research on androgen deprivation therapy duration• NCCN Prostate Cancer Guidelines (discussed throughout the episode)• Artera AI clinical decision support platform (discussion)• Decipher genomic classifier• PSMA PET imaging• MRI-guided prostate cancer staging___________________________________

Florence Comite, MD, a Yale-trained endocrinologist, precision-medicine pioneer, and author of Invincible, explains the five biomarkers that reveal how well you're aging and explores testosterone, metabolic health, cardiovascular risk, biological-age testing, sleep, fertility, and the early warning signs of future disease.This episode is proudly sponsored by:Jaspr is a powerful and beautiful at home air-scrubber that passively makes your home environment healthier by removing allergens, VOCs, dust, pollen, and more, from the air. Get $200 off each one you purchase at https://jaspr.co/genius using code GENIUS.I sleep on an Avocado mattress because real organic materials, no synthetic shortcuts, and better breathability make a noticeable difference. Go to ⁠http://avocadogreenmattress.com/MAX⁠ to check out their mattress and bedding sale.

In this episode, Dr Paul E. Oberstein, Dr Andrew H. Ko, and Dr Efrat Dotan discuss recent advances in pancreatic cancer, including: The evolving role of chemotherapy Utility of tumor treating fields for the treatment of locally advanced pancreatic adenocarcinoma Emerging RAS-targeted strategies and novel approaches for CLDN18.2- and MTAP-altered disease The potential impact of these developments on future treatment sequencing and supportive care  Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Paul E. Oberstein, MD, MS Section Chief, GI Oncology Associate Professor of Medicine Co-Director, KRAS Excellence Initiative Perlmutter Cancer Center NYU Langone Health New York, New York Andrew H. Ko, MD, FASCO Professor of Medicine and Associate Chief Division of Hematology/Oncology University of California San Francisco San Francisco, California Efrat Dotan, MD, MTR Clinical Professor of Medicine (Hematology/Oncology) Executive Medical Director, Penn Medicine, Ann B. Barshinger Cancer Center Penn Center for Cancer Care Innovation, Abramson Cancer Center University of Pennsylvania Philadelphia, Pennsylvania Link to full program: https://bit.ly/44HPR1U Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Stop kidney decline before it starts. See how eGFR and proteinuria trends are reshaping IgA  nephropathy management. Credit available for this activity expires: 7/17/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/translating-emerging-evidence-iga-nephropathy-proteinuria-2026a1000nyb?ecd=bdc_podcast_libsyn_mscped

How much can a 30-second voice clip tell you about your sleep, hydration, and stress levels? Today, I'm joined by Alex Fredericks, the founder of Tonewell, an innovative platform that analyzes the complex waveform and timbre of your voice to deliver highly accurate, actionable wellness reports.Alex breaks down the hard science behind frequency mapping, his transition from the music industry to high-tech wellness, and the hard-hitting entrepreneurial lessons he's learned protecting his peace. We have a refreshing conversation about escaping the data-tracking hamster wheel, setting unapologetic boundaries, and his daily non-negotiables: from daily BJJ and getting his hands in the garden dirt, to his remarkably basic (and hilarious) skincare routine.In this episode, we cover:The jump from music-industry oscilloscopes to wellness frequency.How Tonewell uses Fast Fourier Transfer (FFT) technology to map thousands of biomarkers in five minutes.Escaping data overload: Why choices are more powerful than data.The true definition of success: Time ownership and protecting your boundaries.Non-negotiables for grounding: Barefoot in the garden, daily BJJ, and the ultimate minimalist skincare.Check out Tonewell: tonewell.coConnect with Alex: alexfredericks.comFollow my day-to-day as an NYC creator: https://www.instagram.com/leaura

In this episode of Hema Now, Jorge Cortes reflects on the remarkable evolution of leukaemia treatment throughout his career, from the transformation of chronic myeloid leukaemia outcomes through targeted therapies to the rapidly changing landscape of acute myeloid leukaemia. He discusses the growing importance of biomarkers and patient-reported outcomes, the value of international collaboration, and how precision medicine is reshaping clinical research. Looking ahead, Cortes shares the developments in immunotherapy and personalised care that he believes could define the next era of leukaemia treatment. Timestamps:   00:00 – Introduction   01:01 – Inspiration for Haematology and Leukaemia  02:40 – Transforming Chronic Myeloid Leukaemia Care  04:55 – Future Challenges in CML  07:21 – Evolution of AML Treatment  09:50 – Biomarkers and Personalised Leukaemia Care  11:45 – Balancing Outcomes and Quality of Life  14:02 – International Collaboration in CML  16:33 – The Future of Clinical Research  20:03 – Building a Haematology Academic Career  22:04 – Exciting Advances in Leukaemia Research

I sat down with Dr. Jordan Metzl, a sports-medicine physician who's convinced that the reason most of us can't stay consistent isn't discipline or knowledge, it's motivation, and he says you can actually engineer it by "lowering the cost to act." We get into exercise as a literal medicine that would beat almost any drug if it came in a pill, why fun is the real holy grail of compliance, and how movement can go head-to-head with antidepressants for everyday anxiety and depression. If you've been white-knuckling your way through willpower and losing, this one's going to change how you think about getting off the couch. CLICK HERE TO BECOME GARY'S VIP!: https://bit.ly/4ai0Xwg Get Dr. Jordan Metzl's book, “Push: Unlock the Science of Fitness Motivation to Embrace Health and Longevity”: https://bit.ly/4f28xiO Connect with Dr. Jordan Metzl Website: https://bit.ly/4gzA0tp  Instagram: https://bit.ly/4aRhbhA  Facebook: https://bit.ly/4fdR45E  X: https://bit.ly/4aP5Mig   Thank you to our partners A-GAME: “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij AION: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD AIRES: "ULTIMATE20 " FOR 20% OFF: https://bit.ly/4a3Duze BAJA GOLD: "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa BODYHEALTH: “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV COLD LIFE: THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp CYMBIOTIKA: "ULTIMATE20" FOR 20% OFF: https://bit.ly/4tjyluP GENETIC METHYLATION TEST (UK ONLY): https://bit.ly/48QJJrk GENETIC TEST (USA ONLY): ⁠https://bit.ly/3Yg1Uk9 GOPUFF: GET YOUR FAVORITE SNACK!: https://bit.ly/4obIFDC H2TAB: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg HEALF: 10% OFF YOUR ORDER: https://bit.ly/41HJg6S PEPTUAL: “TUH10” FOR 10% OFF: https://bit.ly/4mKxgcn SNOOZE: LET'S GET TO SLEEP!: https://bit.ly/4pt1T6V WHOOP: JOIN & GET 1 FREE MONTH!: https://bit.ly/3VQ0nzW Watch  the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps 00:00 - ​Intro of Show 02:00 - From family of doctors to sports medicine 04:00 - Prescribing the medicine of exercise 05:55 - What an exercise prescription looks like 07:41 - The 1950s London Transport study 10:22 - Cellular adaptations and mitochondria 11:52 - Inflammation and chronic disease 13:31 - Immuno-fatigue and the theory of aging 14:45 - Motivation, not discipline, is missing 18:14 - Knowledge, emotion, and belief 20:25 - Building a fitness community 24:11 - Biomarkers and the cost of chronic disease 26:23 - Lifespan vs healthspan gap 28:26 - Fun is the holy grail of compliance 34:00 - Why remote work hurts our health 39:16 - Making exercise pay for doctors 41:01 - Two minutes of vigorous activity a day 44:30 - The GLP-1 and arthritic knee study 48:49 - Exercise vs antidepressants 55:38 - Lowering the cost to act 59:42 - What it means to be an Ultimate Human 1:01:29 - Alice: a marathon at 70 Disclaimer: This podcast is for informational purposes only and does not provide medical advice. It is not intended for diagnosing or treating any health condition. Always consult a licensed healthcare professional before making health or wellness decisions.  Gary Brecka is the owner of Ultimate Human, LLC which operates The Ultimate Human podcast and promotes certain third-party products used by Gary Brecka in his personal health and wellness protocols and daily life and for which Ultimate Human LLC and / or Gary Brecka directly or indirectly holds an economic interest or receives compensation.  Accordingly, statements made by Gary Brecka and others (including on The Ultimate Human podcast) may be considered promotional in nature. Learn more about your ad choices. Visit megaphone.fm/adchoices

Can neuroscience strengthen your faith? In this thought-provoking episode of inContext, Michael Easley sits down with neuroscientist Dr. Robyn Honea, whose research has focused on Alzheimer's disease, brain imaging, and neuroplasticity for more than two decades. Together, they explore what modern neuroscience reveals about the incredible design of the human brain—and why our ultimate hope is found not in biohacking or longevity, but in Christ. Dr. Honea shares how years of studying the aging brain led her to publicly integrate her Christian faith with her scientific work. They discuss the fear of dementia, the promise and limitations of medical advances, the role of exercise and healthy habits in brain health, and why believers should steward their bodies without making health an idol. Whether you're caring for aging parents, interested in neuroscience, working in healthcare, or simply wondering how faith and science fit together, this conversation offers biblical wisdom, scientific insight, and lasting encouragement. Topics Covered: Neuroplasticity explained Alzheimer's research and brain imaging Faith and science working together The fear of aging and dementia Brain health, exercise, and lifestyle Supplements, longevity, and biohacking Romans 12 and renewing your mind Music, memory, and dementia Why our identity is more than biology Living with hope as we grow older Chapters 00:00 – Introduction and Meet Dr. Robyn Honea 02:20 – From Schizophrenia Research to Alzheimer's Disease 05:00 – What Is Neuroplasticity? 08:30 – Why Dr. Honea Began Writing About Faith and Science 11:00 – What the Bible Says About Aging 13:00 – Can We Outsmart Aging? 15:15 – Supplements, Longevity & Health Culture 18:00 – Integrating Faith into a Scientific Career 22:15 – The Fear of Aging and Cognitive Decline 26:00 – Brain Scans, Biomarkers & Medical Wisdom 33:00 – Trusting God Instead of Living in Fear 35:00 – Why Music Unlocks Memory in Dementia 37:00 – Romans 12 and Renewing Your Mind 41:00 – Finding Identity Beyond Biology 47:30 – Does Someone with Dementia Still Know You're There? 49:30 – Final Encouragement and Closing Links Mentioned The Honea Lab The Brain God Designed on Substack Watch the highlights and full version of this interview on our Youtube channel. For more inContext interviews, click here.

This week we delve again into the world of adult congenital heart disease and specifically the realm of biomarkers when we review a recent report of the proteomics of the adult Fontan patient. What is proteomics and how can this inform our understanding of the pathophysiology and adaptive pathways of the Fontan circulation? Are there meaningful differences in the patterns of protein expression between the adult Fontan patient and control 2 ventricle subjects? What might account for differences and how can we understand these differences to explain outcomes in the Fontan adult patient? We speak with the first and senior authors of this week's work, Professor Alexander Opotowsky of the University of Cincinnati and Mr. Ismael Assi who is a Sarnoff Fellow and soon to be 4th year medical student at the University of Cincinnati. DOI: 10.1016/j.jacadv.2026.102810 

Why does staying healthy feel harder than it should? In this episode of Beyond the Biomarkers, Kerri Rachelle explores a different perspective on the chronic disease epidemic. What if the problem isn't that we've become lazy or lost our willpower? What if we've simply built a world that's optimized for convenience, speed, and productivity—but not for human biology? You'll learn why your body is often responding exactly as it's designed to, how your environment influences everything from metabolism and energy to inflammation and recovery, and why lasting health is less about motivation and more about intentional design. Rather than chasing perfection, this episode will help you rethink the way you approach your health—one small decision at a time. In this episode, you'll learn: Why healthy choices often feel harder than they should How modern life has changed faster than human biology Why your body isn't broken—it's adapting The role of movement, sleep, relationships, purpose, and environment in long-term health Why motivation fades but good environments create lasting habits How to become an active participant in your own healthcare Simple ways to start designing a life that supports your biology Memorable Takeaways Your body isn't working against you—it's responding to the environment it's been given. The question isn't whether your body is adapting. The question is: what is it adapting to? Health isn't something you find. It's something you design. If this episode resonated with you, share it with someone who needs the reminder that better health isn't built overnight—it's built one decision at a time. Ready for personalized guidance? Our team of functional medicine dietitians at REV0lution helps people across the country uncover root causes, interpret labs, and build sustainable health plans that fit real life. Request an appointment at REV0lution.com. Because our health truly is our happiness.

Which imaging biomarkers matter most at diagnosis of GA, and how should they shape the decision to treat? In episode 1 of the GA in Practice miniseries on New Retina Radio, moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, review the practical role of fundus autofluorescence and OCT in identifying high-risk GA, discuss ellipsoid zone integrity as an emerging endpoint, and work through a hypothetical case of an active, motivated patient with bilateral extrafoveal GA and good vision to explore how lifestyle, lesion characteristics, and patient education factor into early treatment decisions.

EPISODE SUMMARY What if your saliva could predict your brain health, stress resilience, and even your future risk of dementia? In this episode, neuroscientist and biotech entrepreneur Dr. Lavinia Alberi reveals how the future of healthcare is shifting from reactive medicine to real-time precision diagnostics — and why so many ambitious entrepreneurs are unknowingly damaging their cognitive performance in the pursuit of success. We explore the hidden neurological cost of hustle culture, the science of cognitive resilience, and how to build a million-dollar life without sacrificing your brain, body, or relationships. WE TALKED ABOUT … Why dementia may begin decades before the first forgotten name … Neuroscience-based high-performance habits … Why your saliva may reveal more about your health than you think   EPISODE NOTES Dr. Lavinia Alberi is a neuroscientist and biotech entrepreneur with more than two decades of experience decoding the mechanisms of neurodegeneration and dementia. Building on a distinguished academic career — including leadership roles at Johns Hopkins University, Heidelberg University, University of Fribourg, and École Polytechnique Fédérale de Lausanne (EPFL) — she has translated deep scientific insights into innovations advancing precision health, preventive medicine, and therapeutic strategies. As founder and CEO of multiple biotech ventures, including VitalizeDx, Dr. Alberi focuses on salivary biometrics and fluid diagnostics as accessible, non-invasive tools to transform brain health, performance, and disease prevention. Her mission is to leverage cutting-edge science into actionable solutions for athletes, patients, and society at large by strengthening: Cognitive resilience and brain health Muscular reserve and physical performance Immune and metabolic potency Dr. Alberi has raised and managed multimillion-euro research projects, contributed to more than 60 peer-reviewed publications, and holds several patents in precision diagnostics and performance monitoring. In parallel, she serves on scientific and industry boards, including the Alzheimer's Pathobiome Initiative, 5IronmenBeatAlzheimer's, and Chronic Infection Foundation, while actively advocating for democratizing access to precision health. Her vision is to help build a future without sporadic dementia by uniting biotechnology, performance science, and preventive strategies into scalable, high-impact innovations.   Links: https://vitalizedx.ch/ https://www.5ironmansbeatalzheimer.com/ https://www.linkedin.com/in/alberiauber-lavinia/ ------------ Click this link to listen on your favorite podcast player and if you enjoy the show, please leave a rating & review: https://linktr.ee/wiredforsuccess ------------------ Music credit: Vittoro by Blue Dot Sessions (www.sessions.blue) ----------------- Disclaimer: Podcast Episodes might contain sponsored content.

The Ultimate Health Assessment: 400 Biomarkers That Could Save Your Life www.Over40FitnessHacks.comOver 40 Fitness Hacks SKOOL Group!Get Your Whoop4.0 Here!Dr. Clint Phillips - MediciMedici Website:Personal Website: Instagram: @medicihealthDr. Gabi AppIn this episode of Over 40 Fitness Hacks, host Brad Williams sits down with Dr. Clint Phillips, founder of Medici Health, to discuss the future of personalized medicine, AI-driven health optimization, peptides, and preventative healthcare.Dr. Phillips shares his deeply personal journey into longevity science, explaining how losing multiple family members at a young age inspired him to dedicate his career to helping people live longer, healthier lives. After building a successful chiropractic and rehabilitation practice in Aspen, Colorado, and later co-founding a medical second-opinion company following his daughter's stroke, he launched Medici Health with one mission: prevent disease before it starts.The conversation dives into Medici's comprehensive annual health assessment, which collects over 400 health data points through advanced blood testing, DNA analysis, DEXA scans, vascular imaging, skin AI analysis, cancer screening, balance testing, and more. Rather than treating disease after it develops, Medici focuses on identifying each person's unique risk factors and creating highly personalized strategies based on genetics, biomarkers, and lifestyle.Brad and Dr. Phillips discuss why personalized medicine is replacing the "one-size-fits-all" approach to health, highlighting examples where simple lifestyle changes—guided by genetic testing—can dramatically reduce disease risk. They also explore the growing role of artificial intelligence in healthcare, including Medici's AI assistant, Dr. Gabby, which helps users interpret health data, evaluate supplements, scan food products, and even estimate cardiovascular risk using only a smartphone camera.The discussion also covers the rapidly growing field of peptides. Dr. Phillips explains why peptides show tremendous promise for longevity and recovery but emphasizes that they should always be paired with proper laboratory monitoring rather than taken blindly. Brad agrees that objective testing is essential since feeling better doesn't always mean your body is responding positively.Throughout the interview, both emphasize that true health isn't simply avoiding illness—it's building resilience through exercise, nutrition, preventative testing, personalized care, and consistent habits. Dr. Phillips also praises personal trainers as some of the most influential professionals in preventive healthcare, reinforcing Brad's philosophy that fitness coaching remains one of the best investments people over 40 can make.Whether you're interested in biohacking, longevity, AI-powered healthcare, preventative medicine, or simply maximizing your healthspan, this episode provides an insightful look at where the future of healthcare is heading and how personalized data may soon replace generic health advice.If you're interested in online personal training or being a guest on my podcast, "Over 40 Fitness Hacks," you can reach me at brad@over40fitnesshacks.com or visit my website at:www.Over40FitnessHacks.comAdditionally, check out my Yelp reviews for my local business, Evolve Gym in Huntington Beach, at https://bit.ly/3GCKRzVDisclaimer: The information provided on this podcast, including interviews and recommendations, is for educational and entertainment purposes only. It does not constitute medical, nutritional, or professional fitness advice. The hosts and guests are not your personal doctors or trainers. Always consult a qualified medical professional before changing your diet, starting a new exercise regimen, or implementing any advice heard on this show. Use of any information provided is solely at your own risk.

In this episode, I sit down with Dr. Hilary Fritsch, DMD, an airway and biological dentist specializing in jaw development and non-surgical treatment of sleep and breathing disorders. We cover three audiences I care deeply about: parents of children showing signs of airway dysfunction, women in perimenopause who are exhausted and being missed by standard sleep testing, and adults who have been managing symptoms with a CPAP and want to know if there is a better path. Dr. Fritsch explains how mouth breathing, tongue ties, and underdeveloped palates are silently driving ADHD, anxiety, autoimmune disease, and chronic fatigue. She also shares the recent Harvard research on CPAP risks for low-risk patients that genuinely surprised me and why myofunctional therapy alone can cut apnea in half. I share my own journey and my daughter Elle's experience with palate expansion. This episode is packed with actionable information you will not want to miss. What You Will Learn: Why underdeveloped jaws and mouth breathing are a root cause of ADHD, anxiety, and chronic fatigue in children and adults The specific signs of early airway dysfunction in infants and children — and why acting early changes everything Why women are systematically underdiagnosed with sleep apnea and how perimenopause dramatically increases airway collapse risk How non-surgical palate expansion works for adults — no jaw surgery required Why myofunctional therapy is essential for lasting results and can reduce apnea severity by up to 50% What recent Harvard research reveals about CPAP risks for low-risk patients and what to do instead About Dr. Hilary Fritsch Dr. Hilary Fritsch, DMD, is an airway and biological dentist with nearly two decades of clinical experience specializing in jaw development, tongue-tied infants, and the non-surgical treatment of sleep and breathing disorders. She is the founder of Saddle Peak Dental and Western Sleep Solutions in Bozeman, Montana, and she trained extensively under Dr. Kevin Golz, a pioneer in adult palate expansion with over 6,000 cases completed.  Resources and People Mentioned: Vivos Palatal Expansion Candid Clear Aligners Smile Shapers American Academy of Dental Sleep Medicine Why Biological Dentistry & O& Oral Health Hold the Keys to a Healthier You | Dr. Nunnally & Dr. Freeman Connect with Dr. Myers: Website: https://www.dramymyers.com/ Dr. Myers' Inner Circle: https://www.drmyersinnercircle.com/founding-member Newsletter: https://www.amymyersmd.com/pages/newsletter Facebook: https://www.facebook.com/dramymyers Instagram: https://www.instagram.com/dramymyers Connect with Dr. Hilary Fritsch:  Instagram: https://www.instagram.com/hilaryfritchdmd/ Website: https://saddlepeakdunnell.com/ Timestamps: 00:00 Modern Airway Crisis 00:53 Meet Dr Hilary Fitch 03:07 Host Personal Wake Up 05:54 Fitch Origin Story 08:10 Airway Training Maze 10:28 Newborn Jaw Foundations 11:55 Tongue Ties Explained 13:36 Breastfeeding Diet Habits 15:30 Kids Red Flags Checklist 17:57 Adult Symptoms Risks 22:55 Women Menopause UARS 29:16 Four Pillars Fixing Airway 30:15 Nose Palate Remodeling 30:56 Jaw Expansion TMJ Concerns 31:51 Adult Palate Expansion 32:46 Vivos vs Surgical MARPE 33:48 Tongue Space and Myo Therapy 34:22 Kids Expanders and Tooth Pillow 40:05 Compliance and Pain Fears 45:03 Mouth Tape Guidance 46:45 Adult Aligners and Brands 49:22 CPAP Risks and Biomarkers 56:22 Root Cause Wrap Up

What if the real reason most businesses fail isn't strategy or market fit, but the behavior and value system of the owner themselves? In this episode, Sean sits down with Jay Aldebert, a business consultant who has studied patterns across 88,000 businesses and identified 11 biomarkers that predict whether a company will thrive or struggle. Jay explains why he starts every client conversation with a single pointed question about profit, and how the answer reveals far more than most owners expect. He shares why education has to come before measurement, drawing a parallel to how doctors measure without explaining, and why changing an owner's value system is often the hardest and most important part of the work. If you have ever wondered why smart, driven business owners keep hitting the same walls, Jay's framework will give you a completely new lens for looking at your own business.──────────────────────────────────────────────────────

Paul Lingor, MD, is Professor for Neurology, Group Leader and Head of the Outpatient Clinics for Motoneuron Disorders and Co-head of the Outpatient Clinics for Movement Disorders and at the Department of Neurology of the TUM Klinikum Rechts der Isar in Munich, Germany.  Here he discusses the recent publication "Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial."

Could a blood test finally provide answers for millions living with chronic fatigue syndrome (CFS/ME)? In this episode, Alexandre Akoulitchev and Dmitry Pshezhetskiy reveal a groundbreaking approach using epigenetic biomarkers to detect biological signatures associated with this complex, hard-to-diagnose condition. Their work leverages cutting-edge molecular medicine and translational research to provide earlier, more objective detection of CFS/ME—offering hope for patients who have long struggled with uncertainty and delayed diagnoses. In this conversation, we explore: ·       How a blood-based biomarker test may identify chronic fatigue syndrome more reliably. ·       The role of epigenetics in understanding invisible, multi-system illnesses. ·       The four core symptoms of CFS/ME and why conventional diagnostics often fail. ·       How inflammation and immune signals contribute to fatigue and disease progression. Alexandre Akoulitchev, cofounder of Oxford BioDynamics and creator of the EpiSwitch biomarker platform, and Dmitry Pshezhetskiy, Professorial Research Fellow at Norwich Medical School, bring decades of expertise in molecular biology, genome regulation, and translational research to this discussion. Learn more about Alexandre Akoulitchev here and Dmitry Pshezhetskiy here. Episode also available on Apple Podcasts: https://apple.co/38oMlMr 

Hermansky-Pudlak syndrome (HPS) is a rare genetic disorder that causes albinism, bleeding problems, and a high risk of developing pulmonary fibrosis. However, patients with HPS provide an important population for researchers looking for biomarkers that predict the onset and progression of pulmonary fibrosis. On this ATS Breathe Easy podcast episode, expert Resat Cinar, PhD, MBA, National Institute on Alcohol Abuse and Alcoholism, and patient advocate and founder of the Hermansky-Pudlak Syndrome Network Donna Appell, RN, discuss how HPS has helped researchers better understand pulmonary fibrosis, and how research on rare diseases can generate insights that benefit much larger patient populations. 

In this episode, Michel Mommejat, President of A.D.A.M. Innovations, shares how genomics and AI are transforming healthcare from reactive treatment to preventative wellcare. Recorded in Tokyo, this conversation explores what your DNA can reveal as a biological blueprint, why Japan serves as the world's laboratory for healthy aging, and how combining genetic data with biomarkers and lifestyle information creates a dynamic, personalized health ecosystem. Michel also discusses the ethical frameworks needed to protect the most sensitive data that exists, the concept of Artificial General Gene Intelligence, and practical applications like pharmacogenomics that are already changing how we think about medication. Tune in for a visionary conversation on the future of health and longevity.

The migraine pain is gone… so why do you still feel exhausted, emotional, foggy, or completely drained afterward?In this episode of The Migraine Heroes Podcast, host Diane Ducarme explores the often-overlooked “migraine hangover” phase — also known as the postdrome stage. Blending neuroscience with holistic healing insights, this episode explains why your brain and nervous system may still be recovering long after the pain disappears.You'll discover:

On this, our 331st Evolutionary Lens livestream, we discuss sunscreen and vegans. It's Summer, and the sun is out! Should you slather yourself in sunscreen, stay indoors, or seek moderate exposure to the sun that grows in intensity that more your skin becomes acclimated to the season? The last, of course. Research has found that sunscreen use may be positively correlated with skin cancer, but a) “sunscreen” is not just one thing, and most but not all sunscreen is positively toxic, and b) all cause mortality is lower in people who get regular (non-sunscreened) sun exposure, so even if sunscreen does lower your risk of skin cancer—the sun is protecting your health in other ways. Also consider ditching the sunglasses, and donning a hat. Then: even the New York Times can't figure out whose team they're on, as a vegan in Portland tries to get Oregonians to outlaw hunting, fishing, animal research, conventional livestock production, and “lethal pest control.”*****Our sponsors:Mud/WTR: Start your new morning ritual & get up to 43% off your @MUDWTR with code DarkHorse at http://mudwtr.com/DarkHorse #mudwtrpodCaraway: save up to $230 on the 12 piece cookware set vs buying the products individually; include minis duo & save up to $350. Visit http://Carawayhome.com/DarkHorse to take an additional 10% off using code DarkHorse on your next purchase.Puori: Clean and safe supplements, lab tested and guaranteed. Go to http://Puori.com/DarkHorse for 32% off grass-fed whey protein with a subscription. DarkHorse code works on all products!*****Join us on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.comHeather's newsletter, Natural Selections (subscribe to get free weekly essays in your inbox): https://naturalselections.substack.comOur book, A Hunter-Gatherer's Guide to the 21st Century, is available everywhere books are sold, including from Amazon: https://amzn.to/3AGANGg (commission earned)Check out our store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://darkhorsestore.orgMusic: "Marble Machine" by WintergatanThis track can be downloaded for free at www.wintergatan.netFree License to use this track in your video can be downloaded at www.wintergatan.net*****Mentioned in this episode:Hulscher's substack: https://www.thefocalpoints.com/p/study-finds-sunscreen-use-linkedJeremian et al 2023. Gene–Environment analyses in a UK biobank skin Cancer cohort identifies important SNPs in DNA repair genes that may help prognosticate disease risk. Cancer Epidemiology, Biomarkers & Prevention, 32(11): 1599-1607: https://pmc.ncbi.nlm.nih.gov/articles/PMC10840669/pdf/nihms-1929398.pdfNicholson & Exley, C 2007. Aluminum: a potential pro-oxidant in sunscreens/sunblocks? Free Radical Biology and Medicine, 43(8): 1216-1217: https://www.ovid.com/journals/frbm/abstract/10.1016/j.freeradbiomed.2007.07.010~aluminum-a-potential-pro-oxidant-in-sunscreenssunblocksHunter-Gatherer's Guide: https://amzn.to/3AGANGg (commission earned)NYT in Oregon: https://www.nytimes.com/2026/06/21/us/politics/animal-rights-cruelty-oregon.htmlSupport the show

On this episode host Beth Friedman engages Bobby Reddy, Jr., PhD, Co-founder & CEO, Prenosis. Sepsis kills more people annually than all cancers combined - yet it receives a fraction of the research investment. Beth sits with Bobby Reddy Jr., leading Prenosis, a precision medicine company redefining how hospitals understand and treat their most critically ill patients. Reddy explains why decades of clinical trials for sepsis, acute heart failure, and pneumonia have failed and why the solution lies not in new drugs but in recognizing that these are not single diseases at all. Discover how Prenosis is using AI, deep biomarker data, and real-time EHR integration to characterize each patient's unique biology in under an hour, and what a landmark BARDA-funded trial could mean for the future of critical care.

Most athletes get routine blood work.Very few understand which biomarkers truly matter for performance, recovery, and longevity.In this episode of Find Your Edge, Coach Chris Newport and dietetic intern Emily Qiu break down the special lab values endurance athletes should know about and why they matter.We discuss:• CBC and CMP basics• ApoB and cardiovascular risk• Magnesium and athletic performance• Vitamin B12 and MMA• Homocysteine and longevity• Vitamin D and bone health• Why athletes need personalized interpretation• How biomarker trends help you make smarter decisionsIf you've ever felt like you're doing everything right but still not seeing the results you want, this episode is for you.Because the goal isn't more information.The goal is clarity.Learn more about the Endurance Edge Longevity Lab:https://www.theenduranceedge.com/longevity/Check out the episode here: https://www.theenduranceedge.com/special-lab-values-endurance-athletes-biomarkers Support the show

What matters most to patients with non-muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Kelly Bree, Dr. Saum Ghodoussipour, and Meredith Donahue, N.P., join host Dr. Vignesh Packiam to discuss the power of shared decision-making across the NMIBC spectrum. They explore risk-adapted treatment selection, when to escalate or de-escalate therapy, and how to navigate conversations about recurrence risk, treatment burden, quality of life, and the possibility of cystectomy. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Johnson & Johnson. --- Timestamps 00:00 - Introduction01:55 - Second Opinions and Patient Counseling06:08 - Intermediate Risk Stratification12:13 - Treatment Options for Intermediate Risk NMIBC16:20 - BCG and Alternative Treatments for High Risk NMIBC26:49 - Options for BCG-Unresponsive NMIBC31:42 - Sequencing and Cystectomy37:03 - Financial and Time Toxicity41:08 - Biomarkers and ctDNA44:04 - Future Trials and NMIBC Innovations --- More about this episode They also review emerging therapies such as ZUSDURI, the evolving role of intravesical treatments, and the promise of biomarkers and ctDNA for personalized care. The discussion covers practical strategies for patient counseling, key updates to clinical guidelines, and a preview of innovations shaping the future of NMIBC management. --- Resources Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial:https://pubmed.ncbi.nlm.nih.gov/41571573/ Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancerhttps://ascopubs.org/doi/10.1200/JCO-25-01324 CIRCULATING TUMOR DNA AS A BIOMARKER FOR UPSTAGING AND ADVERSE PATHOLOGY IN HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER:https://www.auajournals.org/doi/abs/10.1097/01.JU.0001191388.74345.c9.09 Preoperative Circulating Tumor DNA Predicts Upstaging and Recurrence in High-Risk Nonmuscle-Invasive Bladder Cancer Undergoing Radical Cystectomyhttps://pubmed.ncbi.nlm.nih.gov/41843048/ --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Depression is often treated as a single condition. But two people with the same diagnosis can have completely different underlying causes. On this episode of The Dr. Hyman Show, I'm rejoined by Dr. James Greenblatt to explore why depression may be less of a disease and more of a signal that something deeper is going on. We discuss how a root-cause approach can uncover what's driving symptoms and why finding what's beneath them matters. Watch the full conversation on YouTube or listen wherever you get your podcasts. We discuss: Could nutrient deficiencies, inflammation, or gut issues be contributing to symptoms of depression What tests can help uncover the biological factors that may be affecting mood and mental health Why can two people with depression have different root causes—and require different solutions How do blood sugar imbalances, hormone changes, and metabolic health influence the brain What should you know about antidepressants, tapering, and addressing the factors that may affect recovery Hope doesn't come from ignoring symptoms—it comes from understanding them. Sometimes the most important question isn't "What's wrong with me?" but "What might my body be trying to tell me?" One of the key themes in this conversation is that mental health is deeply connected to what's happening throughout the body. In my Brainshaping Academy, you'll learn how to support the biological systems that shape cognitive, emotional, and mental well-being. View Show Notes From This Episode Depression symptoms aren't always just “in your head.” Dr. Hyman's Brainshaping Academy shows how your gut, immune system, and nutrient levels may be responsible—and what you can do about it. → https://drhyman.com/products/brainshaping?utm_source=dr_hyman_show&utm_medium=newsletter&utm_campaign=may_27&utm_content=link Get Free Weekly Health Tips from Dr. Hyman https://drhyman.com/pages/picks?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Sign Up for Dr. Hyman's Weekly Longevity Journal https://drhyman.com/pages/longevity?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Join the 10-Day Detox to Reset Your Health https://drhyman.com/pages/10-day-detox Join the Hyman Hive for Expert Support and Real Results https://drhyman.com/pages/hyman-hive This episode is brought to you by Seed, Made In Cookware, Perfect Amino, BON CHARGE, and Big Bold Health.Go to seed.com/hyman and use code 20HYMAN to get 20% off your first month.Visit madeincookware.com and use code HYMAN10 for 10% off your order.Go to bodyhealth.com and use code HYMAN20 to get 20% off your first order.Head to boncharge.com/hyman and use code HYMAN for 15% off.Go to bigboldhealth.com/drhyman and use code HYMAN15 to save 15% on your first order. (0:00) Antidepressants, Cooking at Home, and Introducing the Brain Shaping Academy (3:14) Prevalence of Depression and Personal Stories (4:27) Exploring Root Causes of Depression (5:07) Influential Figures and Orthomolecular Psychiatry (12:29) Gut Health, Gluten Sensitivity, and Brain Inflammation (20:22) Neuroinflammation and Root Causes of Depression (22:10) Biomarkers, Hormonal Imbalances, and Insulin Resistance (25:34) The Role of Toxins and Diagnostic Testing (31:15) Case Studies and Patient Stories (34:29) Challenges in the Mental Health System (37:05) Effectiveness of Antidepressants and Patient Resistance (43:17) Role and Need for Nutritional Lithium (45:00) Sponsor: Big Bold Health (46:00) Identifying Nutritional Lithium Need (47:13) Integrating Modalities and Supplements vs. Medications (48:04) Psychotherapy Methods and Addressing Root Causes (49:34) Dr. Greenblatt's Book and the Finding a Living Platform (51:03) Systematic Approach and Global Impact of Depression (52:39) Sharing, Disclaimer, and Closing Remarks

Ready to move beyond “one-size-fits-all” for BCG-unresponsive NMIBC? In this episode of BackTable Urology, Dr. Ruchika Talwar hosts Dr. Sam Chang to discuss the evolving treatment landscape for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). They explore why BCG may fail, the science and clinical rationale behind new immunotherapies and gene therapies, practical approaches to patient selection, treatment sequencing, and surveillance, and the value of emerging biomarkers, empowering urologists to make more informed, personalized decisions in complex cases of NMIBC. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by ImmunityBiohttps://anktiva.com/ --- Timestamps 00:00 - Introduction03:48 - BCG: How it Works and Why it Fails11:13 - Pembrolizumab Role and Limits14:38 - Nadofaragene firadenovec 16:34 - Cretostimogene grenadenorepvec18:39 - BCG + Anktiva Rationale29:50 - Explaining Options to Patients33:05 - Post Treatment Surveillance37:32 - Future of Biomarkers and AI42:05 - Key Takeaways --- Resources N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Reviewhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11524197/ Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancerhttps://doi.org/10.1080/2162402X.2021.1912885 IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancerhttps://evidence.nejm.org/doi/full/10.1056/EVIDoa2200167 --- More about this episode This podcast is for informational purposes only. The views and opinions expressed in this podcast are solely those of the moderator and individual guest. --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

CardioNerds (Dr. Billy-Joe Mullinax, Dr. Dinu Balanescu, and Dr. Jane Ehret) discuss risk stratification in acute pulmonary embolism with Dr. Stavros Konstantinides, Chair of the 2019 ESC Pulmonary Embolism Guidelines. Using a real-world case, this episode explores how modern PE care has moved beyond “massive” and “submassive” labels toward a dynamic, physiology-based approach. The discussion highlights the limitations of static risk scores, the importance of right ventricular dysfunction and biomarkers, and why normotension does not imply stability. Special emphasis is placed on intermediate-high risk PE, early identification of impending hemodynamic collapse, and the role of lactate, serial reassessment, and PERT teams in guiding escalation of care. Audio editing by CardioNerds intern, Joshua Khorsandi.The 2026 American multi-society PE guidelines were published after this episode was recorded. Dr. Dinu Balanescu and Dr. Billy-Joe Mullinax are Co-chairs for the CardioNerds PE Series, developed in collaboration with the PERT Consortium.   Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Pulmonary Embolism PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Stable blood pressure does not mean low risk in PEHypotension is a late finding. Patients may have severe RV failure, hypoxia, and tissue hypoperfusion while remaining normotensive — a key concept behind “normotensive shock.” Risk stratification in PE must be dynamic, not staticLegacy scores like PESI and Bova provide a snapshot and predict 30-day mortality, but they do not capture short-term trajectory or impending hemodynamic collapse. Intermediate-high risk PE is a dangerous and heterogeneous groupPatients with RV dysfunction, positive biomarkers, tachycardia, hypoxemia, and elevated lactate may have in-hospital mortality approaching 15%, rivaling STEMI. Lactate is a critical but underutilized marker in PEElevated lactate reflects tissue hypoxia and early circulatory failure and may identify patients at risk for collapse before blood pressure declines. PERT enables physiology-driven, patient-centered PE carePERT teams operationalize continuous reassessment, integrate imaging, labs, and clinical trajectory, and allow timely escalation — shifting PE management from rigid categories to real-time decision-making. Notes Drafted by Dr. Jane Ehret. 1. What is the contemporary framework for risk stratification in acute pulmonary embolism? Modern PE risk stratification prioritizes hemodynamics and right ventricular (RV) function rather than clot burden. The 2019 ESC Guidelines classify PE into high risk, intermediate risk (low vs high), and low risk, based on: Hemodynamic status, RV dysfunction on imaging, and Cardiac biomarkers. This framework emphasizes early mortality risk but requires clinical context to guide escalation decisions. 2. Why is normotension insufficient to define “stability” in PE? Blood pressure is a late marker of circulatory failure in PE. Patients can maintain normal BP through Tachycardia, Increased sympathetic tone, and RV compensation. Many patients with preserved BP may already have shock physiology, including hypoxemia, elevated lactate, and RV failure — sometimes referred to as “normotensive shock.” 3. How should intermediate-risk PE be conceptualized clinically? Intermediate-risk PE is heterogeneous, ranging from patients who do well on anticoagulation to those who deteriorate rapidly. Intermediate-high risk PE is defined by RV dysfunction on imaging and positive cardiac biomarkers. Clinical features such as tachycardia, increasing oxygen requirement, and elevated lactate identify patients at highest risk within this group. 4. What are the strengths and limitations of commonly used PE risk scores? Legacy scores are useful for initial risk categorization but are static and limited in predicting short-term deterioration. Most scores were developed to predict mortality or complications at fixed time points rather than dynamic clinical trajectory. 5. What are the commonly used risk scores and clinical tools in PE, and what is each designed to predict? ESC Risk Stratification Algorithm: Identifies high-risk PE by hemodynamics. Uses PESI or sPESI in normotensive patients to distinguish low-risk from non–low-risk PE. Uses RV dysfunction and biomarkers to differentiate intermediate-low from intermediate-high risk. Forms the basis of many institutional PE pathways. PESI and sPESI: Validated to predict 30-day mortality. Widely used to identify low-risk patients appropriate for outpatient management. Heavily influenced by age and comorbidities. Bova Score: Predicts 30-day PE-related complications in normotensive patients. Composite PE Shock Score (CPES): Predicts normotensive shock in hemodynamically stable PE patients. Pulmonary Embolism Progression (PEP) Score: Predicts progression from intermediate-risk to high-risk PE within 72 hours of diagnosis. PE Short-term Clinical Outcomes Risk Estimation (PE-SCORE): Predicts clinical deterioration or death within 5 days of PE diagnosis. Hestia Criteria: Identifies low-risk PE patients safe for outpatient treatment. Wells' Criteria and Revised Geneva Score: Determine pretest probability for diagnostic triage. PERC Score: Rules out PE in very low-risk patients. 6. What is the role of biomarkers in PE risk stratification? Troponin and natriuretic peptides reflect RV myocardial injury and strain. Current guidelines treat biomarkers as binary (positive vs negative), despite risk being continuous. Biomarkers are most helpful for: Initial risk classification. They are less useful for: Short-interval monitoring and Detecting rapid clinical deterioration. 7. Why is lactate an important physiologic marker in PE? Lactate reflects global tissue hypoxia and impaired perfusion. Elevated lactate may identify patients with: Early circulatory failure and Increased risk of imminent hemodynamic collapse. Lactate is not currently included in ESC risk algorithms but may add important prognostic information in intermediate-risk patients. 8. How does trajectory influence decision-making in PE management? Risk stratification should be viewed as a dynamic process, not a one-time label. Worsening clinical trajectory may include: Rising heart rate, Increasing oxygen needs, Rising lactate, and Progressive RV dysfunction. Serial reassessment is essential for timely escalation of care. 9. What role do Pulmonary Embolism Response Teams (PERT) play in risk stratification? PERT facilitates: Multidisciplinary decision-making and Integration of imaging, biomarkers, and clinical physiology. PERT is most valuable for: Intermediate-risk and high-risk PE and Patients with complex comorbidities or uncertain trajectory. PERT enables a shift from category-based to physiology-driven PE care. References 1. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 2019;54(3):1901647. Published 2019 Oct 9. doi:10.1183/13993003.01647-2019 2. Leidi A, Bex S, Righini M, Berner A, Grosgurin O, Marti C. Risk Stratification in Patients with Acute Pulmonary Embolism: Current Evidence and Perspectives. J Clin Med. 2022;11(9):2533. Published 2022 Apr 30. doi:10.3390/jcm11092533 3. Choi WH, Kwon SU, Jwa YJ, et al. The pulmonary embolism severity index in predicting the prognosis of patients with pulmonary embolism. Korean J Intern Med. 2009;24(2):123-127. doi:10.3904/kjim.2009.24.2.123 4. Jiménez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170(15):1383-1389. doi:10.1001/archinternmed.2010.199 5. Chen X, Shao X, Zhang Y, et al. Assessment of the Bova score for risk stratification of acute normotensive pulmonary embolism: A systematic review and meta-analysis. Thromb Res. 2020;193:99-106. doi:10.1016/j.thromres.2020.05.047 6. Zhang RS, Yuriditsky E, Zhang P, et al. Composite Pulmonary Embolism Shock Score and Risk of Adverse Outcomes in Patients With Pulmonary Embolism. Circ Cardiovasc Interv. 2024;17(8):e014088. doi:10.1161/CIRCINTERVENTIONS.124.014088 7. Zhang RS, Alam U, Sharp ASP, et al. Validating the Composite Pulmonary Embolism Shock Score for Predicting Normotensive Shock in Intermediate-Risk Pulmonary Embolism. Circ Cardiovasc Interv. 2024;17(2):e013399. doi:10.1161/CIRCINTERVENTIONS.123.013399 8. Ehret J, Wakefield D, Badlam J, Antkowiak M, Erdreich B. Development of the Pulmonary Embolism Progression (PEP) score for predicting short-term clinical deterioration in intermediate-risk pulmonary embolism: a single-center retrospective study. J Thromb Thrombolysis. 2025;58(2):243-253. doi:10.1007/s11239-024-03051-5 9. Weekes AJ, Raper JD, Lupez K, et al. Development and validation of a prognostic tool: Pulmonary embolism short-term clinical outcomes risk estimation (PE-SCORE). PLoS One. 2021;16(11):e0260036. Published 2021 Nov 18. doi:10.1371/journal.pone.0260036 10. Zondag W, Hiddinga BI, Crobach MJ, et al. Hestia criteria can discriminate high- from low-risk patients with pulmonary embolism. Eur Respir J. 2013;41(3):588-592. doi:10.1183/09031936.00030412 11. Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med. 2001;135(2):98-107. doi:10.7326/0003-4819-135-2-200107170-00010 12. Wolf SJ, McCubbin TR, Feldhaus KM, Faragher JP, Adcock DM. Prospective validation of Wells Criteria in the evaluation of patients with suspected pulmonary embolism. Ann Emerg Med. 2004;44(5):503-510. doi:10.1016/j.annemergmed.2004.04.002 13. Le Gal G, Righini M, Roy PM, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med. 2006;144(3):165-171. doi:10.7326/0003-4819-144-3-200602070-00004 14. Kline JA, Mitchell AM, Kabrhel C, Richman PB, Courtney DM. Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. J Thromb Haemost. 2004;2(8):1247-1255. doi:10.1111/j.1538-7836.2004.00790.x 15. Kline JA, Courtney DM, Kabrhel C, et al. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria. J Thromb Haemost. 2008;6(5):772-780. doi:10.1111/j.1538-7836.2008.02944.x

Gina, a perinatal fitness trainer, birth doula, and founder of MamasteFit in North Carolina, explains how exercising during pregnancy improves quality of life during pregnancy and postpartum—not just birth outcomes—while noting prenatal exercise research is still limited. She highlights a 2025/2026 American Journal of Obstetrics and Gynecology systematic review (11 RCTs) finding the strongest biomarker benefits from 12+ week programs done 2–3 times/week at moderate-to-vigorous intensity, including reduced pro-inflammatory markers, improved glucose/insulin regulation (supporting lower gestational diabetes risk), better lipid regulation, and favorable hormone/growth-factor changes linked to placental function and possibly baby brain development. Another 2025 review (9 RCTs, 1,500+ participants) suggests strength training may reduce excessive weight gain, low back/sciatic pain, and improve mood, sleep, fatigue, and well-being. She also cites studies indicating high-intensity lifting and even Valsalva can be well-tolerated with adequate rest and self-monitoring, then outlines MamasteFit's endurance-focused programming (compound lifts, accessory multi-plane work, myofascial slings, and posterior-chain emphasis) and promotes their app/video programs with a discount code.00:00 Why Prenatal Exercise Matters00:46 Meet Gina and MamasteFit01:38 What Research Can Tell Us02:23 Biomarkers and Training Dose05:11 Inflammation and Glucose Control08:05 Lipids Hormones and Baby Brain10:46 Strength Training Quality of Life13:17 Heavy Lifting and Valsalva Safety18:03 Listening to Your Body18:58 How to Program Prenatal Lifting20:54 Movement Variety and Posterior Chain23:04 Programs and Final Takeaways————

What if your genes are not your destiny, but a set of clues your body has been giving you all along? In this episode, Dr. Taz sits down with Dr. Florence Comite, endocrinologist, clinician scientist, longevity expert, and author of Invincible: Defy Your Genetic Destiny to Live Better, Longer, to explore how biomarkers, genetics, hormones, sleep, metabolism, and family history shape the way we age.In this episode, Dr. Comite explains why longevity is not just about biohacking, supplements, peptides, or the latest wellness trend. Instead, she shares why true healthspan begins with understanding your own body, your own patterns, and your own family story. She explains how changes in blood sugar, fasting insulin, free testosterone, cholesterol risk ratio, sleep quality, muscle, and metabolism can reveal early signs of disease risk long before symptoms fully appear.Dr. Taz and Dr. Comite discuss why “normal” lab ranges are not always the same as optimal health, why some people begin showing signs of metabolic disease decades earlier than expected, and how family history can act as a powerful roadmap for prevention. They also explore how genetics, lifestyle, hormones, wearables, continuous glucose monitoring, sleep, movement, protein, and personalized medicine may help people change the trajectory of their future health.If you're listening to this and thinking, “I know something is off in my body, but I don't know where to start,” join the Circle here:

The number one side effect of comfort is chronic disease, and we're more comfortable than any generation in human history. In this episode, Dr. Clay Moss and I unpack the simple, foundational shifts that produced life-changing results in a 7-day in-patient metabolic rehabilitation protocol: full elimination diet, sleep hygiene, intentional movement, stress management, and community connection. No biohacking gadgets required. Just a return to the basics, your biology was built for. CLICK HERE TO BECOME GARY'S VIP!: https://bit.ly/4ai0Xwg Listen to "Off Label with Dr. Clay Moss" on all your favorite platforms! YouTube: https://bit.ly/4defyfj  Spotify: https://bit.ly/4t5CbY7  Connect with Dr. Clay Moss Website: https://bit.ly/4cGbCE7  YouTube: https://bit.ly/423HwEo  Instagram: https://bit.ly/4mZqjoZ  Facebook: https://bit.ly/4teExEk  TikTok: https://bit.ly/423KkkU  X: https://bit.ly/3R88atg  LinkedIn: https://bit.ly/4cVVAVx  Thank you to our partners A-GAME: “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij  AION: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD  AIRES: "ULTIMATE20 " FOR 20% OFF: https://bit.ly/4a3Duze  BAJA GOLD: "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa  BODYHEALTH: “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV  COLD LIFE: THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp  CYMBIOTIKA: "ULTIMATE10" FOR 10% OFF: https://bit.ly/4tjyluP  GENETIC METHYLATION TEST (UK ONLY): https://bit.ly/48QJJrk  GENETIC TEST (USA ONLY): ⁠https://bit.ly/3Yg1Uk9  GOPUFF: GET YOUR FAVORITE SNACK!: https://bit.ly/4obIFDC   H2TABS: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg  HEALF: 10% OFF YOUR ORDER: https://bit.ly/41HJg6S  PEPTUAL: “TUH10” FOR 10% OFF: https://bit.ly/4mKxgcn  SNOOZE: LET'S GET TO SLEEP!: https://bit.ly/4pt1T6V  WHOOP: JOIN & GET 1 FREE MONTH!: https://bit.ly/3VQ0nzW  Watch  the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps 00:00 ​Intro of Show 04:18 Metabolic Syndrome Definition 06:00 Dr. Clay Moss's Medical Journey 16:05 Biomarkers to Start 23:14 Functional Medicine Program 28:25 Stress Management Protocols 21:35 GLP-1: Pros and Cons 37:21 Future of Peptides 41:42 When Should People Take Peptides, GLP-1? 47:54 Muscle as Our Metabolic Currency 53:14 Female Hormone Therapy Benefits 58:04 Dr. Clay Moss's Mission-Vision 1:03:38 How to Improve Sleep Hygiene 1:08:08 Connect with Dr. Moss 1:08:40 What does it mean to you to be an Ultimate Human? Disclaimer: This podcast is for informational purposes only and does not provide medical advice. It is not intended for diagnosing or treating any health condition. Always consult a licensed healthcare professional before making health or wellness decisions. Gary Brecka is the owner of Ultimate Human, LLC which operates The Ultimate Human podcast and promotes certain third-party products used by Gary Brecka in his personal health and wellness protocols and daily life and for which Ultimate Human LLC and / or Gary Brecka directly or indirectly holds an economic interest or receives compensation.  Accordingly, statements made by Gary Brecka and others (including on The Ultimate Human podcast) may be considered.  Learn more about your ad choices. Visit megaphone.fm/adchoices

“The awareness of how lifestyle, diet, and exercise affect us is mind-blowing.” Dr. Giovanni Campanile and Dr. Sandra Cammarata are the founders of CorAeon, the only functional medicine practice founded and led by a husband-and-wife team. Campanile is a Harvard-trained functional cardiologist, Associate Professor of Medicine at Rutgers, New Jersey Medical School, and former cardiologist for the President of the United States, George H.W. Bush. Cammarata is a Tufts-trained functional psychiatrist with 36 years of experience and multiple Castle Connolly Top Doctor honors. Together, they treat cardiovascular health and mental well-being as one inseparable system. They are co-authors of The Sicilian Secret Diet Plan and hosts of the podcast The Rest is Health. 00:00 - The mind-body approach to heart health 03:01 - How relationships predict lifespan 05:18 - The Monday morning heart attack 09:13 - Where healthy people get tripped up 13:02 - Visceral fat & body composition testing 15:28 - Biomarkers beyond cholesterol 23:25 - The problem with a zero CAC score 25:09 - Medications for heart disease risk 28:22 - When stress is the real driver 31:46 - EXO Mind & magnetic brain stimulation 35:34 - The problems with traditional cardiology 41:00 - The benefits of sauna therapy 44:46 - The hidden epidemic: insulin resistance 47:57 - The future of heart health Referenced in the episode:  Harvard longevity study: https://www.adultdevelopmentstudy.org/  This podcast is sponsored by CorAeon, the only functional medicine practice created by a functional cardiologist and functional psychiatrist team for a true mind-body approach. Learn more at coraeon.com.  We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Full Show Notes: https://bengreenfieldlife.com/trupodcast In this episode with repeat guest Dr. Matt Dawson, you’ll discover how epigenetic testing analyzes DNA methylation to reveal how fast you’re biologically aging, what’s driving your health, and your risk for disease. You’ll explore how these signals can detect chronic disease risk earlier than traditional labs, and how TruDiagnostic built the TruHealth Test by analyzing ~1,000 biomarkers to pinpoint the most meaningful health indicators. We also break down the TruAge Test, covering biological age, pace of aging, and organ-specific aging, plus insights from my own results. We discuss how AI and large language models (LLMs) identify which interventions actually improve specific biomarkers, and what truly moves the needle for longevity, from caloric restriction and GLP-1 drugs to the often-overlooked impact of relationships, stress, and recovery.